Skip to main content

Peer Review reports

From: Comparison of warfarin, rivaroxaban, and dabigatran for effectiveness and safety in atrial fibrillation patients with different CHA2DS2-VASc scores: a retrospective cohort study

Original Submission
6 Nov 2023 Submitted Original manuscript
29 Mar 2024 Reviewed Reviewer Report
9 Apr 2024 Reviewed Reviewer Report
17 May 2024 Author responded Author comments - Shiwei Xu
Resubmission - Version 2
17 May 2024 Submitted Manuscript version 2
31 May 2024 Reviewed Reviewer Report
5 Jun 2024 Reviewed Reviewer Report
19 Jun 2024 Author responded Author comments - Shiwei Xu
Resubmission - Version 3
19 Jun 2024 Submitted Manuscript version 3
21 Jun 2024 Author responded Author comments - Shiwei Xu
Resubmission - Version 4
21 Jun 2024 Submitted Manuscript version 4
24 Jun 2024 Author responded Author comments - Shiwei Xu
Resubmission - Version 5
24 Jun 2024 Submitted Manuscript version 5
27 Jun 2024 Reviewed Reviewer Report
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
27 Jun 2024 Editorially accepted
16 Jul 2024 Article published 10.1186/s12872-024-04020-9

You can find further information about peer review here.

Back to article page